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Abstract 
Marek’s disease (MD), caused by Marek’s disease virus (MDV), is a commercially important neoplastic disease of poul-
try which is only controlled by mass vaccination. Importantly, vaccines that can provide sterile immunity and inhibit 
virus transmission are lacking; such that vaccines are only capable of preventing neuropathy, oncogenic disease and 
immunosuppression, but are unable to prevent MDV transmission or infection, leading to emergence of increas-
ingly virulent pathotypes. Hence, to address these issues, developing more efficacious vaccines that induce sterile 
immunity have become one of the important research goals for avian immunologists today. MDV shares very close 
genomic functional and structural characteristics to most mammalian herpes viruses such as herpes simplex virus 
(HSV). MD also provides an excellent T cell lymphoma model for gaining insights into other herpesvirus-induced 
oncogenesis in mammals and birds. For these reasons, we need to develop an in-depth knowledge and understand-
ing of the host-viral interaction and host immunity against MD. Similarly, the underlying genetic variation within 
different chicken lines has a major impact on the outcome of infection. In this review article, we aim to investigate the 
pathogenesis of MDV infection, host immunity to MD and discuss areas of research that need to be further explored.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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1 Introduction
Characterized after its human orthologue (Herpes Sim-
plex Virus; HSV a DNA containing virus), Marek’s dis-
ease virus (MDV), or Gallid herpesvirus 2 (GaHV-2), the 
etiologic agent for Marek’s disease (MD) is an alpha-her-
pes virus that targets avian species (Gallus gallus domes-
ticus) where it establishes chronic infection. Notably 
recognized as a multifaceted disease, MD is characterized 
based on immunosuppression, neurological disorders 
and neoplastic transformation of CD4+ T cells, localised 
around peripheral nerves and visceral organs of the host 
[1]. Since the late 1960s, both large and small scale poul-
try production systems have been dependent on vaccine 
use for disease control. Although not a notifiable disease 
according to the World Organization for animal health 
(OIE), disease distribution is acknowledged as worldwide 
although precise estimates of morbidity, annual eco-
nomic loses and report of disease distribution on each 
continent are lacking. Effective global surveillance for 
MDV requires accuracy of reporting source and compre-
hensiveness. Current data from OIE estimates that about 
half of the world countries have reported cases of MDV 
infection (Figure 1). As global requirement increases, so 
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facilities. The control of MDV infection is arguably very 
challenging due to its ubiquitous presence at the expense 
of already pre-established biosecurity programs.
Several MDV pathotypes have been characterised over 
the years based on morbidity and mortality rates [2]. 
These pathotypes can be distinguished into three sub-
families (GaHV-2, GaHV-3 and MeHV-1) based on bio-
logical and genomic similarities: GaHV-2 (RB-1B, Md5 
and CVI988/RISPENS), GaHV-3 (SB-1) and MeHV-1 
(HVT; FC-126). Like all herpes viruses, MDV is strictly 
cell associated. MeHV-1 also known as the Herpes 
Virus of Turkey (HVT/FC-126) is non-pathogenic in 
chickens and turkeys [3], but can induce viremia, which 
is associated with the induction of protective immu-
nity against MD. Chickens infected with HVT become 
persistently infected and maintain long-lasting immu-
nity. Comparative genomic analysis identified sequence 
similarities, features and structures to that of infectious 
MDV (GaHV-2) antigens [4]. Live HVT (FC-126 strain) 
in combination with SB-1 and 301B/1 are widely used 
in bivalent and polyvalent vaccine formulation to pro-
vide enhanced protection against GaHV-2, but they 
became less effective with the emergence of highly vir-
ulent MDV. The most effective vaccines developed to 
date is CVI988/RISPENS (GaHV-2) vaccines [5] which 
provides protective immunity against disease progres-
sion (oncogenesis and neuropathy; transient and acute 
paralysis) but not sterile immunity (establishment of 
primary infection and shedding of mature virus par-
ticle) which is complicated by reactivation of virus 
particles from latency. Since its introduction, global 
vaccination efforts have been efficacious in controlling 
disease outbreaks thus increasing poultry operations 
productivity and reduced losses associated with large 
scale culling of diseased chickens. MD is the first onco-
genic disease for which an effective vaccine has been 
developed. New surging evidence suggests that current 
vaccination protocol, whether imperfect [6] may be 
acting in synergy with a plethora of environmental fac-
tors resulting in MDV genetic drifts [7–9]. The human 
alpha-herpes virus, HSV and Varicella Zoster Virus 
(VZV) [10] are well documented with similar pathogen-
esis to MDV. The Oka vaccine provides highly protec-
tive immunity against VZV primary infection (chicken 
pox) and controls viral dissemination (virus reactiva-
tion from latency in nervous system cells), unlike the 
CVI988/RISPENS strain. In MD, although clinical onset 
of disease has been controlled with implementation of 
vaccination programs, MDV continues to infect and 
replicate into fully infectious virus particles in vacci-
nated chickens; followed by the shedding of these highly 
contagious, cell-free mature virions from the feather 
follicle epithelium into skin dander and poultry dust. All 
these make MDV environmentally persistent as well as a 
highly infectious and contagious pathogen of chickens. 
In this review article, we discuss recent progress made 
in understanding MDV pathogenesis and immunity, aim 
to scrutinize the pathogenesis of MDV infection, host’s 
immunity to MD and outline areas of research that need 
to be further explored.
Figure 1 Worldwide map depicting distribution of MDV whereby evidence for presence has been submitted to the OIE. Distribution 
data was obtained from the World Organization for Animal Health (OIE) distributed through the World Animal Health Information Database (WAHIS) 
interface and summarized above based on absence (blue) and presence of disease with reported cases (red) before and after 2009. A World map 
depicting countries positive for MDV was constructed using the imapbuilder software. Both China and Egypt (black) are endemic areas for MDV 
with outbreaks reported on a yearly basis. B Pie chart demonstrates the number of countries that have reported MDV cases to the OIE based on 
their geographical location (continent). Data is summarized based on absence (blue), and presence of disease with reported cases (red).
Page 3 of 19Boodhoo et al. Vet Res  (2016) 47:119 
2  Pathogenesis of Marek’s disease
2.1  Marek’s disease
MDV, the causative agent of MD in chickens, result in 
transformation of CD4+  T cells. The natural route of 
infection is defined by inhalation of airborne cell-free 
virus particles within the contaminated dust and dander 
(Figure  2), shed from infected host produced in termi-
nally differentiated feather follicle epithelium [11], into 
a naïve respiratory track [12]. MD pathogenesis has four 
phases in the susceptible birds; an early cytolytic phase 
within 2–7 days post-infection (dpi) which delineates as 
semi productive lytic viral replication in lymphocytes. 
This is followed by a latency phase that occurs between 
7 and 10 dpi in CD4+  T cell subset that result in sys-
temic viral dissemination. Cutaneous viral infection can 
occurs as early as 4 dpi and eventually results in fully 
productive viral replication and shedding [13]. MDV 
reactivation in CD4+ T cells initiates a late cytolytic and 
immunosuppressive phase starting around 18 dpi. Finally 
a proliferative phase around 28 dpi [14, 15] is character-
ized by formation of visceral tumours that originate from 
CD4+ T cells lymphoma. There is no transmission from 
chicken to eggs (vertical transmission) but the birds are 
usually infected in early stage after hatching (horizon-
tal transmission). The presence of maternal antibody 
against MD can protect the neonatal chicks, and with the 
Figure 2 Model of MDV infectious life cycle in resistant birds. MDV infection of naive host occurs via inhalation of dust or skin dander 
encapsulated viral particles into the respiratory tract. 1 Primary infection occurs when virus particle breaks mucosal tolerance in the lungs, site of 
entry into the epithelial cells. Local viral replication establishes infection and initiates viral immediate-early gene, viral Interleukin-8 (vIL-8), transcrip-
tion and translation. Inflammatory responses in the underlying tissue recruit innate immune system cells which result in uptake of infectious virus 
particle by macrophages. Infiltration of lymphocytes via action of vIL-8 follows resulting in MDV infection of B-cells. 2 Viral replication in B cells initi-
ates Semi Production Lytic Viral Infection and disease progression. MDV infected B cells secret vIL-8 that acts as a chemotactic factor for and gains 
access to T-cells. This specific lymphotropism (B cells and T cells) enables systemic disseminated viraemia. Viral replication causes apoptosis of B and 
T lymphocytes in a hallmark of immunosuppression. MDV integrates specifically into the genome of CD4+ T cells enabling escape from immune 
detection and initiates Latent Viral Infection. Early latently infected and activated CD4+ T cells have not been phenotypically characterised by cell 
surface markers. a Early latently infected and activated CD4+ T cells migrate to cutaneous sites of replication namely feather follicle. 3 Infection 
of feather follicle epithelium enables fully productive viral replication. Viral replication results in syncytia formation. Infection of feather epithelium 
leads to secretion of mature virion in skin danders and dust that act as the major source of infectious materials. Horizontal transmission is the only 
recognized form for environmental persistence and infection in field conditions. Systemic infection and neoplastic transformation of CD4+ T cells in 
susceptible birds is further discussed (Figure 3).
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development of a functional immune system a degree of 
resistant to MD is developed [5]. However, husbandry-
related stress or concurrent infection with other immu-
nosuppressive pathogens such as chicken infectious 
anaemia virus (CIAV), reovirus and infectious bursal dis-
ease virus (IBDV), significantly enhances susceptibility to 
MDV [5]. Another important factor in the susceptibility 
to MD is the genetic background of chicken lines which 
is to some extent associated with the major histocompat-
ibility complex (MHC). However, it should be noted that 
MHC does not necessarily play a critical role in resist-
ance or susceptibility to MD. Chicken lines 6-3 and 7-2 
harbour the same MHC haplotype (B2/B2) while line 6-3 
is relatively resistant and line 7-2 is highly susceptible 
to MD. It has been demonstrated that some very viru-
lent (vv+) strains of MDV induces tumours even in the 
resistant line 6-3. MDV-associated lymphoma can only 
be developed in genetically susceptible chickens; how-
ever the virus can replicate and shedding still occurs in 
both susceptible and resistant chicken lines.
2.2  Establishment of primary infection
It is speculated that lung epithelial cells are one of the pri-
mary target cells for MDV infection. MDV antigens, with 
well-defined expression during cytolytic and latent phase 
of replication, have been detected at significant levels at 
various time points in lung epithelial cells in ovo [16], 
and in vivo [17] suggesting an establishment of successful 
infection. The later was performed via an aerosol method 
which simulates natural infection as a respiratory disease 
[12]. Viral replication in the lungs could be detected as 
early as 1 dpi. Purchase et al. [18] were among the first to 
demonstrate a novel route for high replication kinetics of 
infectious MDV antigens in lungs epithelial cells of chicks 
inoculated via intra-abdominal route. However when 
they repeated the experiment, a lower immunofluores-
cence was detected at 5 dpi compared to 7 dpi. The route 
of administration, whether intra-abdominal or intra-tra-
cheal might affect viral replication as well as systemic dis-
semination that results in MD [19]. In addition, infection 
of lung resident antigen presenting cells (APCs), such as 
macrophages, is thought to result in subsequent trans-
port to primary and secondary lymphoid organs such 
as thymus, bursa of fabricius, and spleen [20]. Although 
it is unclear whether macrophages and lung epithe-
lial cells get infected simultaneously or rather infected 
lung epithelial cells may play a role in transmitting viral 
particles to macrophages. It is evident that post MDV 
infection, immune responsiveness leads to macrophage 
infiltration although viral replication is unaffected [17]. 
It is also believed that presence of MDV particles in the 
lung, during the earliest infection, stimulates secretion 
of cytokines and chemotactic factors that help in attract-
ing B cells to site of infection [21, 22]. One of the defined 
chemokine is a viral IL-8 which is similar to CXCL13 and 
is involved in recruiting immune systems cells to site of 
viral replication [23] and is defined as a homologue to the 
host IL-8 gene. IL-8 has a well-defined role as a chemot-
actic molecule for T cell [22, 24] and B cells [22]. Immune 
cells recruited to the lung such as B cells can be detected 
as early as 2 dpi [25].
2.3  Semi productive lytic viral replication
MDV has a specific tropism for immune system cells and 
preferentially infects lymphocytes; B cells and T cells 
(αβ). Infection of B cells may occur in the lung and viral 
replication in B cells is defined as semi-productive lytic 
viral replication. Lytic activity due to viral replication has 
been linked to phosphoprotein 38 (pp38) activities [26, 
Figure 3 Model of MDV neoplastic transformed CD4+ T cells 
and subsequent disseminated Systemic Infection in suscepti-
ble birds. 4 Fully latent MDV-Transformed CD4+ T-cells proliferate in 
all sites where immune systems cells are involved in primary and sec-
ondary line of defence. Early latently activated CD4+ T cells undergo 
neoplastic transformation due to transcriptional and transrepressional 
activity of viral oncogenic proteins such as Meq. Pathogenesis arise 
in cases where vaccination failure is suspected (suboptimal dosage/
titre, damage to vaccine or confirmed immunological vaccine 
failure), vaccination is not performed (backyard birds). b Fully latent 
neoplastic MDV-Transformed CD4+ T cells infiltrate and establish a 
reservoir of MDV genome in peripheral nerve fibres interspace. These 
cells have a CD4+ CD25+ Treg phenotype although additional cell 
surface markers have yet to be determined. Expression of viral neu-
rovirulence factor, phosphoprotein 14 (pp14), promotes neuropathy 
and cell survival. Neuropathy (Polyneuritis) is presented as transient 
or acute paralysis of legs, wings, neck, with vision impairment and 
weight loss depending on MDV-1 virulence factor. Birds infected with 
serotype-1 eventually succumb to death from paralysis. c Reactiva-
tion from latency enables a second phase of replication whereby viral 
oncogenic protein Meq acts on T cell signaling pathways causing 
uncontrolled cellular proliferation leading to disseminated lymphoma 
formation in visceral organs, peripheral and central nervous system, 
musculoskeletal systems, skin and eyes. Severe lymphoma eventu-
ally causes death in birds. Highly pathogenic viruses (serotype-1, 
vv+ MDV) kill birds before they reach the lymphoproliferative phase 
of the disease.
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27]. PP38 role as an early immediate gene is defined only 
in lymphocytes, specifically B cells and T cells [28, 29]. 
It has been shown that an MDV rMd5Deltapp38 dele-
tion mutant for pp38 lacked the ability to induce cytol-
ytic activity characterized by B cell apoptosis [30]. This 
is in accordance with the notion that recruitment of 
lymphocytes such as B cells to site of viral replication is 
a key step for transmission of virus and dissemination. 
Deletion mutants of vIL-8 (RB1BvIL-8ΔsmGFP) when 
tested in vivo showed a reduced capacity to successfully 
infect lymphocytes and induce lytic infection [23]. A 
lack of IL-8 therefore result in impaired ability to recruit 
B cells and as well as an observable reduction in cytol-
ytic activity due to reduced viral titer and dissemination 
by lymphocytes. Infection with wild-type MDV restored 
lytic activity and viral dissemination to primary lymphoid 
organs [28]. Viral lytic activity in B cells results in a dras-
tic downfall in the overall antibody production and ability 
to fight against an infection. Consequently, the infected 
chicken suffers from immunosuppression, making it 
more susceptible to MD and other infections [31]. Dur-
ing the early cytolytic phase, transcriptional modification 
and epigenetic changes (DNA methylation, histone post-
translational modifications and non-coding RNAs), along 
with post-transcriptional and post-translational modifi-
cations, regulate viral replication cycle and subsequent 
expression of cellular and viral genes. Either way, it’s been 
postulated that disseminated viremia to various organs 
in a cell associated manner results in systemic infec-
tion. Infected B cells may also be able to produce vIL-8 
mRNA which would have chemotactic activity for T cells. 
Infected B cells therefore are able to recruit T cells which 
would allow for transmission of MDV virus particle from 
infected B cells to activated T cells. Viral replication in T 
cells also lead to cytolysis associated with pp38 activity. 
The RB1BvIL-8ΔsmGFP deletion mutant lacked the abil-
ity to attract B cells and subsequently impaired its ability 
to infect T cells albeit at a lower frequency [23]. Further-
more, MDV preferentially targets CD4+  T cell subsets 
and infection results in viral latency and immune evasion 
[22].
2.4  Immune evasion and latency
Hereafter, MDV enters the latency phase (Figure 2) such 
that it can no longer be detected by the host immune 
system while it continues to replicate inside the lym-
phocytes [15]. One of the important immune evasion 
strategies include down regulation of MHC I molecules 
on infected lymphocytes. A specific gene, encoding for 
viral RNA telomerase (vTR) subunit, has been reported 
to be present only in the oncogenic MDV pathotypes, 
but not in their non-oncogenic counterparts. In addi-
tion, further study has confirmed about 88% identity 
of the vTR gene with the chicken terminal repeat (cTR) 
gene of the host. This would mean that vTR gene is 
also complement to host Telomerase reverse tran-
scriptase (TERT) for cTR. Consequently, MDV and 
other herpes virus integrate at the ends of host’s chro-
mosomes, preferably at TR sequences. It is, therefore, 
thought that vTR subunit might, in fact, have a signifi-
cant role in maintaining the viral oncogenicity through 
telomeric elongations at the host’s chromosomal ends 
thereby inhibiting programmed cell death through tel-
omere shortening [32]. However, it has recently been 
shown that both oncogenic and vaccinal strains of MDV 
have the ability to integrate into DNA, suggesting that 
integration alone is not sufficient for MDV-induced 
transformation [33]. Chromosomal insertions of alpha-
herpes virus DNA segments, including those from 
HSV and equine herpes virus types 1 and 3, have been 
associated with their oncogenesis, because many of the 
cells carrying integrated viral DNA displayed a trans-
formed phenotype [32]. Consistent with this, Delecluse 
et al. [34] has demonstrated evidences of MDV genome 
integration into host’s chromosomes for all lymphoma 
established, MDV cell lines. Additionally, expression of 
MDV-Meq gene is essential for MDV-induced neoplas-
tic transformation of latently infected cells (Figure  3). 
Meq expressed specifically by oncogenic GaHV-2 has 
transcriptional activities that lends to modulation of 
host genomic activity. In relation to this, Lupiani et al. 
[35] conducted a study using a recombinant Md5 patho-
type, attenuated by deletion of Meq-gene. As expected, 
MDV did infect and replicate in the lymphoid organs 
and feather follicles; but there was no tumour induction, 
implicating that the integrating viral genome requires a 
Meq gene for induction and maintenance of oncogenic 
properties. Reactivation of MDV from latency and tum-
origenic transformation of latently infected lympho-
cytes mainly occurs in CD4+ T cells [36].
Another important factor in the susceptibility to MD 
is the genetic background of established chicken lines. 
MDV-associated CD4+  T cell lymphoma can only be 
developed in genetically susceptible chickens; however, 
the virus can replicate and be shed from both susceptible 
and resistant chicken lines. It should be noted that highly 
pathogenic strains of MDV can induce T cell lymphoma 
in the resistant chicken lines. It is believed that only a few 
subsets of CD4+  T lymphocytes undergo transforma-
tion, and thus are the origin of lymphoma [1]. This may 
explain why in most cases of MD tumour cells obtained 
from different anatomical sites, such as liver, kidneys, 
gonads, skin and muscles, all have similar CDR3 length 
profile suggesting that tumour cells are monoclonal [37]. 
In most lymphoma cells, the virus is in the latent phase 
and does not produce viral particles and only 0.1% of 
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tumour cells are in the lytic phase [38]. Omar and Schat 
[26] have revealed an association between the genetic 
background of chickens and their resistance to MDV; in 
relation to slight variations on MDV associated-MHC 
presentations between resistant (B21) and susceptible 
(B19) chicken lines. These studies showed evidences of 
T cell mediated immune responses against the MDV 
antigen, ICP4, only in the resistant chicken lines; but not 
in the susceptible ones. In contrast, both B21 and B19 
chicken lines have been reported to show T cell immune 
responses against the other three MDV antigens: gB, Meq 
and pp38. Nevertheless, these studies suggest that T cell 
mediated responses in combination with MHC play an 
important role in genetic resistance against MD.
2.5  Cutaneous infection, replication and shedding
Viral genomes are detectable by quantitative PCR in 
blood cells and feather tips of birds infected with onco-
genic or vaccinal strains [13]. Similar to other herpes 
viruses, MDV has a tendency to be transported towards 
cutaneous sites such as skin, and feather follicles. MDV is 
shed into the environment via scales and feather debris, 
which is a major source of contamination [12, 39]. It is 
possible that T cells transport the virus to feather fol-
licles, but the role of other immune cells in transport-
ing the virus has not yet been ruled out. Infiltration 
of CD4+  and CD8+  T cells and expression of pro-
inflammatory cytokines into the skin of birds infected 
with a highly virulent virus (like RB-1B) or by a vaccine 
strain of the virus (like Rispens or HVT) suggest that 
the immunity against the virus is ineffective at blocking 
virus replication and shedding [40, 41]. Cell-free MDV is 
only produced in feather follicle epithelial cells, and it is 
believed that MDV relies exclusively on cell-to-cell trans-
mission [42, 43]. However, in a recent report, this notion 
has been challenged by demonstrating that in a cell-
blebbing phenomenon and cell apoptotic corps clearance 
mechanism, MDV can be transmitted in a cell-free con-
dition [44]. Meq expressing tumour tissues can also be 
found in the skin of infected birds and neoplastic cutane-
ous lesions in the scaleless chickens indicates that feather 
follicles are not necessary for skin tumour development. 
Finally, the data indicate that inoculation with superna-
tant fluid from homogenized and sonicated skin sam-
ples of MDV-infected scaleless chickens induces MD in 
susceptible birds, suggesting that skin epithelial cells not 
associated with feather follicles also harbour infectious 
viral particles [45]. The process of apoptotic corps clear-
ance may well be related to its specific tropism for adap-
tive immune cells which leads to immunosuppression. It 
is still unclear whether either phenomenon also occurs 
in  vivo during the early hours of infection or vaccina-
tion as well as the respective cells involved. Furthermore, 
vaccinated challenge birds don’t show clinical signs of 
immunosuppression therefore an inherent resistance to 
cellular apoptosis is observed. This may have important 
implications in our understanding of MDV pathogen-
esis and development of next generation MDV vaccines. 
MDV can be detected in the feather follicles at around 
11–14 dpi, using standard biochemical methods, and 
6–7 dpi, using sensitive methods such as qPCR. In cuta-
neous sites, fully productive infection and replication is 
re-activated in feather-follicle epithelium and enveloped 
infectious viral particles in a cell free form are released. 
MDV can be found in the epithelium of feather follicles 
infected chickens more frequently than other tissues, 
both, in terms of incidence and levels of viral antigen 
expression [46]. The virus replicates as enveloped, cell 
free MDVs in the feather follicles epithelium of infected 
chickens. These cell-free MDVs are highly infectious and 
are easily released into the poultry dust or litter. They 
have a very protective envelope, allowing them to survive 
for months in poultry thus facilitating horizontal trans-
mission and infection of naïve animals in following pro-
duction cycles [47].
MDV infection and its global presence could also be 
a product of natural reservoirs located in backyard and 
migratory birds (Figure 4) such as Common teal, White-
fronted goose, Pintail, European wigeon, and Mallard 
[48] and more recently in Roulroul partridges [49]. The 
presence of MDV in wild and migratory birds has been 
well documented since the early 1980. So it is of no 
great surprise that new reports emerge as these viruses 
cause disease in newly identified host. Further monitor-
ing is required to understand the importance of wild 
birds as reservoirs along migratory routes for pathogenic 
serotypes.
2.6  Infection of immune cells
Based on the current model of MDV pathogenesis, 
phagocytic cells such as macrophages and dendritic cells 
in the respiratory tract become infected either directly 
or after an initial round of viral replication. The virus 
can also replicate in macrophages and induce cytoly-
sis in the infected phagocytic cells as demonstrated by 
high levels of cell death in splenic macrophages express-
ing three herpesvirus kinetic classes: ICP4 (immediate 
early), pp38 (early) and gB (late). The level of infection in 
macrophages isolated from MDV-infected birds depends 
on the virulence of MDV. The in  vivo results demon-
strate that, at 4–6 dpi, more virulent viruses (C12/130) 
induce 3–10 times higher percentages of pp38+  mac-
rophages compared to that infected with less virulent 
MDV. The results also show that pp38+  macrophages 
are prone to cell death. Interestingly, MDV antigens 
could only be detected in MDV infected macrophages, 
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but not in uninfected macrophages that have phagocy-
tosed MDV infected cells [20]. Consistent with this view, 
Abdul-Careem et al. [17] have shown an up-regulation in 
nitric oxide synthase (NOS) gene in lung macrophages 
of MDV infected chickens. This results in production of 
nitric oxide (NO) reported to have anti-microbial activity 
against many viruses including MDV for both in vivo and 
in  vitro conditions [20]. Likewise, a similar distribution 
profiles of MDV antigen have been observed in MDV 
infected B lymphocytes during the early cytolytic phase. 
Replication of MDV in the lung induces host innate 
immune response as demonstrated by up-regulation of 
Toll-like receptors (e.g. TLR 3 and TLR 7), pro-inflam-
matory cytokines (e.g. IL-1β and IL-8) and iNOS genes 
as well as infiltration of macrophages [17]. However, 
mucosal immune response to MDV in the lungs is inef-
fective in controlling virus replication [17, 20, 25].
Generally, the infection of mammalian immune cells 
such as macrophages and B cells with herpes viruses 
down-regulates the expression of both MHC class I and 
II molecules consequently, evading hosts’ cell mediated 
immunity [50]. It has been shown that MDV infection 
down-regulates surface expression of MHC (B com-
plex) class I (BF) glycoproteins during active but not 
latent infection of chicken cells [51]. Further studies 
demonstrated that MDV012 and MDV pUL.49.5 genes 
(Table 1) are involved in down-regulation of MHC class 
I molecules by interfering with transporter associated 
with antigen processing (TAP) function. However, the 
effects of MHC class I down-regulation in the pathogen-
esis of the disease is unknown and recombinant viruses 
lacking the cytoplasmic tail of pUL49.5 exhibit almost 
similar pathogenicity as wild type virus in both the resist-
ant and susceptible chicken lines [52, 53]. NK cells and 
more importantly cytotoxic T lymphocytes (CTL) which 
monitor cell surface MHC class I molecules and viral 
peptide complex respectively may play a major role in 
host defence against infection. Contrary to MHC class 
I, MDV infection up-regulates MHC class II molecules 
on chicken APC’s such as macrophages [54, 55], and this 
may contribute to virus spread within the infected host by 
increasing the interaction between infected macrophages 
and activated CD4+  T cells. Since MDV requires cell-
to-cell contact for virus spread and productive infection 
of T cells and other immune cells, this up-regulation of 
MHC class II molecules might, in fact, be essential in the 
pathogenesis of MD within the infected host by increas-
ing the interaction between infected macrophages and 
activated CD4+ T cells [51, 54]. HIV infection can also 
induce activation of innate response and up-regulation 
of MHC class II molecules which can lead to immuno-
pathology [56, 57]. It is still unclear whether MHC class II 
up-regulation observed after MDV infection can induce 
immunopathology which is clearly manifested in MDV 
pathogenesis. In the infected cells, MDV virus expresses 
a viral antigen with high amino acid sequence homology 
to CXCL13, termed viral IL-8 (vIL-8). CXCL13 exerts its 
chemotactic effects by interacting with chemokine recep-
tor CXCR5 and is a major regulator trafficking for B cells 
and subsets of T cells. This viral chemokine has the abil-
ity to recruit immune cells to the site of infection [23]. 
The deletion of vIL-8 from open reading frames severely 
affects MDV pathogenesis and tumour incidence [22, 23, 
58]. vIL-8 induces chemotaxis of B cells and regulatory 
T cells (CD4+  CD25+  T cells), and these cells are tar-
gets for both lytic and latently infected cells, thus dem-
onstrating a virus specific tropism [22]. Within 24  h 
Figure 4 Model for horizontal and vertical transmission of 
MDV between avian species. MDV serotypes can infect several 
different avian species globally. It has been confirmed that MDV 
cannot be transmitted horizontally from layer hens to eggs but day 
old chicks become infected in broiler production housing systems 
from shedders. Several avian species have been grouped based on 
literature: Free ranging and farm animals and Migratory birds. Chicken 
red mites have also been identified as carriers of avian pathogens. 
Free ranging and farm animals consist of turkeys, common pheasant, 
common grey partridge and European quail. Migratory birds that 
have been confirmed positive are ducks and white footed geese. 
Although these birds become infected and are carriers, what has 
not been identified is their role in viral virulence factors as well as 
ability to infect broiler production system. Furthermore, the presence 
of chicken red mites has yet to be confirmed in broiler production 
system which could contribute to viral persistence.
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after infection, the virus can be detected in the bursa of 
Fabricius, spleen, and thymus [14, 15]. It is believed that 
macrophages and dendritic cells can disseminate the 
virus from the lungs to B cells and CD4+ T cells in these 
lymphoid organs. Splenic B cells play an important role 
in the replication of MDV, and the high titre of circulat-
ing virus is due to the replication of the virus within B 
cells, but in the absence of B cells, the virus replicates in 
other immune cells and MD can still be developed. In the 
cytolytic phase of the disease, large number of splenic B 
cells undergoes apoptosis and cell death. Depletion of B 
cells and CD4+ T lymphocytes in lymphoid tissues, such 
as cecal tonsils (CTs), of susceptible chicken lines within 
5 dpi may contribute to immunosuppression observed 
in late cytolytic phase of the disease. The depletion of B 
and T cells in the CTs of the resistant line was minimal 
at 5 dpi, which also recovered by 21 dpi [59]. Virus repli-
cation in B and T cells reaches its peak between 3 and 7 
dpi. B lymphocytes constitute the majority (around 90%) 
of cytolytically infected (MDV-antigen positive) cells, 
while CD4+  and CD8+  T lymphocytes represent only 
3 and 8%, respectively [60, 61]. MDV can be transmitted 
directly to T cells from the infected macrophages or den-
dritic cells; however, the transfer of virus from B cells to 
T cells is also conceivable.
Cytolytic infection of B and T cells is semi-productive, 
which is defined by their inability to express certain viral 
structural components. No cell-free virus is produced by 
the infected T and B lymphocytes and only non-envel-
oped intra-nuclear particles are detected [5]. The precise 
mechanism as to how in vivo MDV spreads from cell to 
cell has not been elucidated. However, it is assumed that 
MDV glycoproteins (g) B, gC and gD, similarly observed 
in most herpes viruses, are likely to interact with host’s 
cell surface receptors; thereby, forming an intracellu-
lar bridge between infected and uninfected cells which 
Table 1 MDV genes and their respective products involved in immune modulation and pathogenesis
MDV gene (protein) Function Antigenic potential Infection stage Reference
MDV003/078 (vIL-8) Viral chemotactic (CXCL-) protein involved in recruiting 
immune systems cells to site of viral replication
– Lytic replication [23, 58]
MDV010 (vLIP) Shares homology to host lipase enzyme and forms cova-
lent bonds with lipids
– Lytic replication [136]
MDV011/012 Immune evasion protein that down regulates cell surface 
MHC I expression
– Lytic replication [52]
MDV012 ORF012 Phosphoprotein required for viral growth both in vivo and 
in vitro
– [137]
MDV040 (gB) Hypothetical function: Virion membrane protein that het-
erodimerizes with other glycoproteins facilitating viral 
fusion with host membrane
Yes Lytic replication [26, 27]
MDV052/053 UL39/40 (RR) Viral Ribonucleotide Reductase (RR) is essential for replica-
tion both in vivo and in vitro
– Lytic replication [138]
MDV064 (UL49.5) Partially reduces MHC I expression by interacting with TAP 
protein
– Lytic replication [53]
MDV073 (pp38) Early protein expressed during cytolytic infection and 
phosphorylated by Us3p
Yes Lytic replication [26–29]
MDV092 (Us3p) Serine/threonine protein kinase that phosphorylates pp38 – Lytic replication [139]
MDV084/100 (ICP4) Viral gene transactivation function Yes Lytic replication [26, 27]
MDV001a (vTR) Required for integration of viral genome into host DNA 
for immune evasion, neoplastic transformation and 
viraemia
– Latency [140]
MDV006 (pp14) Neurovirulence factor required for PNS neuropathy (acute 
or transient paralysis)
– Latency [141]
MDV062 (VP22) Tegument protein essential for viral replication and modu-
lates host cell cycle
– Latency [142]
MDV057 (gC/UL44) Type 1 transmembrane protein required for horizontal 
transmission/shedding from feather follicle epithelium
– Feather follicle shedding [143]
MDV005/076 (MEQ) Viral oncogenic protein involved in T cell neoplastic 
transformation which forms homodimers and heterodi-
mers with specific intracellular signalling proteins that 
modulates host cell cycle
Yes Neoplastic transformation [26, 27, 35]
MDV029 (pUL17) Co-localizes with VP5 and VP13/14 tegument protein and 
essential for in vivo viral growth, capsid maturation and 
DNA packaging
– Neoplastic transformation [144]
Page 9 of 19Boodhoo et al. Vet Res  (2016) 47:119 
might, in turn, contribute to cell associated viral spread 
in MD. Similarly, co-existence of MDV gH and gL have 
been reported to be vital for GaHV-2 cell to cell viral 
spread. The primary peptide of gL has a high affinity for 
specific region of gH, and therefore binds to it giving rise 
to a complex, hetero-oligomer structure that anchors 
itself onto the cell surface of infected host cell, promot-
ing MDV proteins (gp) cell surface expression [62]. In 
support, Schumacher et al. [63] demonstrated that dele-
tions of gE (20DeltagE) or gI (20DeltagI) were essential 
in restricting viral spread and plaque formation, although 
viral replication was not abolished. Transfecting gE or 
gI did not support viral spread indicating that gE and 
gI could work in synergistic manner to aid viral spread. 
Furthermore, it is possible that MDV mainly replicates 
within B and T cells by mitosis of infected cells rather 
than production of virions. Thus, MDV does not require 
expressing all the viral genes to replicate in vivo. By not 
producing all the MDV viral antigens that may be highly 
immunogenic, the virus can escape immune control. This 
notion is supported by the fact that the resting T cells, 
with low proliferative abilities, are less susceptible to 
MDV infections than the activated lymphocytes. T cell 
activation may increase the expression of surface mol-
ecules that is engaged in virus entry, thus enhancing the 
occurrence of MDV infection in these cells.
Similar to MDV, the infection of human CD4+  T 
cells by human T cell leukaemia virus type 1 (HTLV-1) 
is increased in activated CD4+ T cells. This is reflected 
on up-regulation of heparan sulfate proteoglycans 
(HSPGs), a receptor for HTLV-1, on activated CD4+  T 
cells [64]. No specific receptor for MDV entry into 
chicken CD4+ T cells has yet been identified. It is con-
ceivable that MDV infection induces cytolysis/inflamma-
tory responses and T cell activation, which leads to T cell 
infection and viral replication via mitosis by passing the 
virus to daughter lymphocytes.
The underlying genetic variation within different 
chicken lines may play a key role in the pathogenesis and 
prognosis of the MDV infection. The percentages of T 
cells that become cytolytically infected in the lymphoid 
organs are less than 2% in MD-susceptible chickens and 
0.2% in the resistant chickens [5, 60]. In support, Omar 
et  al. [26] have demonstrated evidences of T cell medi-
ated immune responses against the MDV antigen, ICP4, 
only in resistant (B21) chicken lines; but not in susceptible 
(B19) ones. In contrast, both B21 and B19 chicken lines 
have been reported to show T cell immune responses 
against MDV antigens: gB, Meq and pp38. Neverthe-
less, these studies suggest that the role of T cell mediated 
immunity, and differences in T cell receptor repertoire 
generation in conjuncture with other inherent genetic 
resistance mechanism against MD cannot be ruled out. 
In latent phase of infection, MDV antigens cannot be 
detected in the lymphoid tissues and there is no produc-
tion of infectious viruses. It is difficult to distinguish latent 
infection from transformation phase, as both represent 
non-productive infections. Following in  vitro reactiva-
tion of MDV from virus antigen-negative lymphocytes, 
the majority of latently infected lymphocytes were iden-
tified as T cells with only 3% being B cells [5]. Meq anti-
gen from MDV plays a crucial role in maintaining latency 
by blocking apoptosis of latently infected CD4+  T cells. 
One of the pronounced differences in gene expression 
profile between MDV-resistant and susceptible chicken 
lines after MDV infection are genes that are associated 
with apoptosis [65]. In addition to Meq, it has been shown 
that microRNA miR-M3, an MDV-encoded miRNA, 
abrogates apoptosis by directly targeting Smad2, a criti-
cal component in the transforming growth factor (TGF)-β 
[66], providing an environment beneficial for latency and 
oncogenesis. miR-M4, an ortholog of the oncogenic miR-
155, was shown to have a direct effect on inducing MDV-
induced T cell lymphoma, as viruses deleted in miR-M4 
or having mutations in the seed region failed to induce 
lymphoma [67]. Viral miR-M4 exerts its effects by reduc-
ing the levels of latent TGF-β binding protein-1, which 
is involved in the maturation of TGF-β. This leads to a 
reduction in the levels of active Smad2/3 and release of 
the inhibition of the c-Myc promoter, resulting in a rise 
in c-Myc transcription. The production of viral protein 
Meq allows the formation of complexes with c-Myc [68], 
which is associated with transformation. In the suscepti-
ble chickens, a second wave of semi-productive infection 
and cytolysis are observed between 14 and 21 dpi [14]. 
This late cytolytic phase is associated with immunosup-
pression, atrophy of lymphoid tissues such as thymus, 
bursa of fabricius, cecal tonsils and infiltration of mono-
nuclear cells and heterophils [14, 69]. Virus is probably 
transferred to the skin by latently infected CD4+ T cells 
and infects skin and feather follicles in a yet unknown 
mechanism. Syncytia formation in skin epithelium may 
be a product of viral protein which facilitates and pools 
greater resources for viral replication. The involvement 
of other immune system cells such as macrophages and 
dendritic cells to transport the virus to the skin cannot be 
excluded. Replication of MDV starts at 7 dpi, well before 
tumour development. Therefore, it is possible that early 
infected CD4+ T cells, but not necessarily latent or trans-
formed CD4+ T cells, transport the virus into the skin at 
this time.
3  The immune response to MDV
3.1  Innate immunity
While effective immunity against human alphaherpesvi-
ruses relies on both innate and adaptive mechanisms, the 
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innate immune response has been shown to be of para-
mount importance [70]. Less is known about the role of 
innate immunity in the control of MDV in chickens.
3.1.1  Interferons
Type I IFNs belong to a family of cytokines that attracted 
much attention owing to their protective role against viral 
infection. IFNs are widely expressed cytokines that pos-
sess strong antiviral and immunomodulatory properties. 
The IFN family can be classified into three main types of 
cytokines—type I, type II and type III IFNs. IFN-α and 
IFN-β belongs to type I IFN family, while the type II IFN 
family includes only one cytokine: IFN-γ, which also 
exhibits antiviral activities [71]. The third type of IFNs is 
the IFN-λ family. In mammals, plasmacytoid dendritic 
cells (pDCs), monocytes, epithelial cells and fibroblasts 
are the main producers of type I IFNs [72], while type 
II IFNs are predominantly produced by NK cells and 
activated T cells. In spite of the fact that chicken type I 
IFNs are shown to inhibit viral infection both in vivo and 
in vitro, chicken pDCs have not been identified.
Chickens become infected with MDV via the respira-
tory system by inhaling infected dust. MDV is taken up 
by phagocytic cells such as macrophages or dendritic 
cells within the respiratory system. Chicken lung has 
a different anatomical structure than the mammalian 
counterpart consisting of air sacs; and due to narrower 
pulmonary capillaries than in mammals there are fewer 
airway resident macrophages [73]. Therefore, it is likely 
that MDV has to cross lung epithelial lining before being 
transported by phagocytic cells to lymphoid tissues. 
In the respiratory system, the virus can be recognized 
by TLRs, such as TLR21 (recognizing unmethylated 
CpG DNA), leading to the initiation of protein signal-
ling cascaded which stimulates the expression of type I 
interferons (α and β), shown to be involved in antiviral 
defence. In fact, an increase in the expression of TLR 
receptors in the lungs of MDV-infected birds [36], IFN-α 
expression in the blood of susceptible chickens [74] and 
interferon regulatory factors (IRF)-1 and IRF-3 in MDV-
infected chicken embryonic fibroblasts cells (CEF) have 
been reported [75, 76]. The role of IFNs in the control 
of MDV replication has been confirmed in an in  vitro 
model showing that IFNs reduces plaque formation and 
expression of PP38 and gB in the infected cells [77]. The 
protective role of IFNs is also indicated by the results 
demonstrating the differential expression patters of IRF-3 
and IFN-β genes in resistant and susceptible chicken lines 
[78]. Similarly, oral administration of IFN-α are shown to 
reduce MDV viral replication in vivo [79].
In addition to their direct effects on viral replication, 
type I interferons may also activate other immune sys-
tem cells such as natural killer (NK) cells and increases 
their cytotoxic function [80]. However, it has been sug-
gested that chicken NK cell cytotoxicity is not increased 
after oral administration of recombinant chicken IFN-α 
or inoculation of recombinant MDV expressing chicken 
IFN-α (rMDV-cIFN-α). In chickens inoculated with 
rMDV-cIFN-α, NK cell cytotoxicity was not enhanced 
over control chickens at 4 and 7 dpi. Furthermore, at 
4 dpi, chickens inoculated with R2/23 actually had 
decreased NK cell cytotoxic activity. Therefore, it is con-
cluded that ChIFN-α, given at high doses orally in the 
drinking water or via expression in a recombinant MDV 
vector, does not increase NK cell cytotoxicity as originally 
hypothesized [79]. The suppression of immune responses 
by oral administration of IFN-α is not a novel phenom-
enon as similar observations are reported in murine 
model where, bone marrow functions were suppressed by 
administration of murine IFN-α orally or subcutaneously 
[81]. In fact, it has been shown that type I IFNs modu-
late the function of both innate and adaptive immune 
cells including DCs and T cells in the gut and suppress 
the intestinal inflammation. Taken together, it is believed 
that type I IFN response by MDV-infected cells promotes 
the activation of immune cells and inhibits MDV repli-
cation and dissemination. Considering the complexity of 
MDV and co-evolution of the virus with the host’s type 
I IFNs response, it is very likely that there is a complex 
relationship between MDV and host response. The exact 
role of type I IFNs in the pathogenesis of MDV in chick-
ens is poorly understood due to lack of immunological 
reagents, complexity of MDV infection and the cell-type 
specific effect of type I IFNs. However, it is possible that 
type I IFNs may be involved in promoting latency infec-
tion of MDV as has been observed in other alphaherpes-
viruses [82].
The role of type II IFNs, IFN-γ, is discussed in more 
detail in adaptive immunity section. IFN-γ is induced 
during MDV infection and shown to have inhibitory 
effects on MDV replication by inducing nitric oxide pro-
duction [77] and the administration of IFN-γ with MDV 
vaccine positively influenced vaccine-induced protective 
immunity in  vivo [83]. There is no information on the 
role of type III IFNs on viral infections in chickens.
3.1.2  Macrophages and dendritic cells
There is very little information on the type and func-
tion of antigen presenting cells (APCs) involved in the 
initiation of immune responses against MDV in the 
respiratory system of chickens. However, it is believed 
that chicken professional APC’s such as macrophages 
and dendritic cells play an important role in the devel-
opment of adaptive immunity against MDV. In mam-
mals, it has been shown that dendritic cells play a crucial 
role in linking innate to adaptive immunity. The type 
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of dendritic cells and the type of maturation induced 
by different stimuli influences the immunological out-
come, such as differentiation of Th1 vs. Th2 type T cells. 
There is very limited information on the role of den-
dritic cells in MDV immunity, however, it is postulated 
that these cells could be involved in the initiation of 
innate and adaptive immunity against MDV. In addition 
to their ability to present MDV antigens in association 
with MHC class I and II molecules to initiate adaptive 
immunity, macrophages can also be directly involved in 
inhibition of MDV replication and development of MD. 
Macrophages isolated from B21 chickens have higher 
phagocytic activity than B19 chickens to MDV [84]. 
Moreover, macrophages obtained from MDV-infected 
chickens inhibited viral replication in  vitro more effi-
ciently than macrophages isolated from non-infected 
chickens [85]. Further confirmation on the role of mac-
rophages in MDV infection is obtained from the results 
demonstrating that depletion of macrophages from sple-
nocytes increases MDV replication [84], while stimulat-
ing macrophages in  vivo reduces the incidence of MD 
[86]. Taken together, the evidence presented here from 
several studies confirms that macrophages play a pivotal 
role in control of MDV replication and MDV-derived 
tumour incidence. One of the mechanisms involved in 
the inhibitory function of macrophages on MD is their 
ability to produce inducible nitric oxide (iNOS). The 
production of NO has been reported in the spleen, brain 
and lungs of MDV-infected chickens [13, 77, 87, 88] and 
NO is shown to inhibit MDV replication with highest 
level of NO production detected in serum and spleen 
of resistant chickens compared to susceptible chick-
ens [77, 89]. Further experiments demonstrated that 
the inhibition of iNOS in chickens increases viral load, 
suggesting that NO plays an important role in the con-
trol of MDV replication in  vivo [77]. Another function 
of macrophages is their ability to kill tumour cells and it 
is believed that activated chicken macrophages have the 
ability to lyse MDV-derived tumour cells in vitro [90]. In 
contrast to activated and fully functional macrophages, 
tumour associated macrophages (TAMS) represent 
key regulators of the complex interplay between the 
immune response and cancer. TAMS produce tumour 
growth promoting factors and induce immunosuppres-
sion by releasing immuno-modulatory factors [91]. Mac-
rophages isolated from tumour tissues of MDV-infected 
chickens demonstrate similar functional abilities as 
TAMS and have been shown to suppress T cell prolif-
eration in vitro. The development of immuno-regulatory 
macrophages in MDV-infected chickens correlates with 
transient immunosuppression observed during primary 
cytolytic phase of infection [92], suggesting that TAMS 
may be involved in MDV-induced immuno-suppression.
3.1.3  Natural killer (NK) cells
NK cells represent important effectors of the innate 
immunity and can respond to stimuli and produce anti-
viral cytokines such as IFN-γ. In addition, these cells have 
ability to recognize virus- infected cells/tumour cells via 
ligation of cell death receptors and the release of gran-
ules. NK cells from MDV-resistant chickens have higher 
cytotoxic capability than the MDV-susceptible chickens, 
suggesting that these cells may be involved in determin-
ing resistance to MDV. This hypothesis is also supported 
by the results demonstrating that MDV-infected chickens 
have higher NK cell activity than the cells isolated from 
the non-infected birds and; this activity lasted longer in 
the resistant chickens than the susceptible chickens [93]. 
The exact role of NK cells in providing vaccine-induced 
protection against MDV is still unknown, however, 
there are some evidences demonstrating that vaccina-
tion against MDV increases the functional abilities of NK 
cells. This may explain how MDV vaccine can provide 
protection in vaccinated chicks as early as 3  days post-
vaccination [93]. NK cells also play a fundamental role as 
antitumor senses through downregulation of cell surface 
markers such as MHC I. A notable characteristic of her-
pes viral infection and specifically MDV is down regula-
tion of MHC I cell surface translocation. Further to that, 
anti-tumor activity has not yet been demonstrated in an 
MDV resistance model independent of genetic factors 
that predispose resistance to neoplastic transformation 
of CD4+ T cells. Taken together, it has been suggested 
that NK cells may play an important role in controlling 
MDV infection [93–95]. Using recently identified mark-
ers such as CD56 and CHIR-AB1 [96] for identification 
of chicken NK cells, researchers will be able to elucidate 
the role of these important cells in providing protection 
against MDV.
3.2  Adaptive immunity
The key components of adaptive immunity are B and 
T lymphocytes which specifically recognize antigens 
and generate memory response. B cells are involved in 
humoral immune response, whereas T cells are involved 
in cell-mediated immune response.
3.2.1  Humoral immunity
As MDV is a cell-associated herpes virus and is strictly 
intracellular, antibodies should not have a major role in 
the protective immunity against MDV infection. How-
ever, antibodies against several MDV glycoproteins 
including gB, gE, gI have been detected in MDV-infected 
birds [97, 98]. The role of these antibodies in providing 
protective immunity against MDV has not been clarified. 
However, there is some evidence suggesting that anti-gB 
neutralizing antibody may have a protective role against 
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MDV, perhaps via blocking virus entry into the host 
cells or antibody dependent cell-mediated cytotoxicity 
(ADCC) of infected cells. The role of antibody response 
in the control of MDV infection is also confirmed by 
the fact that the presence of maternal antibody delays 
the development of clinical signs and tumour. However, 
the presence of maternal antibody can interfere with 
live replicating vaccines against MDV by neutralizing 
the vaccinal virus [5]. Therefore vertical transmission of 
immunological factors such as maternal antibodies can 
be a limiting factor for both generations of protective 
immunity as well as delaying immune responsiveness to 
infection challenge models of offspring from vaccinated 
layers. Maternal antibody and interference with vacci-
nation has been reported in both human and veterinary 
medicine regardless of the types of vaccine formulations 
used. It has been shown that while maternal antibody 
can interfere with antibody response, vaccine-induced 
cell-mediated immune responses are largely unaffected. 
This has been confirmed in humans, murine models 
and farmed animals [99–104]. With regard to the inhibi-
tory effect of maternal antibody response, new strate-
gies have been developed to overcome the inhibitory 
effects of maternal antibody on vaccine-induced anti-
body response. For example, it has been shown that the 
induction of type I interferon in vivo strongly stimulates 
B cell responses and restores antibody levels after immu-
nization in the presence of maternal antibodies. One way 
of inducing high levels of type I interferon is the com-
bined use of TLR-3 and TLR-9 agonists as adjuvants for 
immunization [102]. Therefore, it should be possible to 
overcome the neutralizing effects of maternal antibody 
against MDV in novel vaccination strategies.
3.2.2  Cell‑mediated immunity
Antibody and cell mediated immunity is involved in the 
control of infection with highly cell-associated human 
alphaherpesviruses such as VZV. Both CD4+  and 
CD8+  effector and memory T cells are shown to be 
essential for recovery from VZV and maintaining the 
latent stage of infection in the subclinical state. Generally, 
it is believed that (a) broad (response to several epitopes), 
(b) durable (memory response), and (c) multi-functional 
(capable of producing several Th1 type cytokines/kill 
virus infected cells) T cell response is associated with 
the control and resolution of viral infections. MDV is 
also a highly cell-associated alphaherpesvirus, and thus 
it is postulated that cell-mediated immunity is crucial for 
the vaccine induced protection [105, 106]. Since MDV 
exists in cell associated forms inside the host, except in 
feather follicles, T cell mediated immunity is thought to 
be more important than the antibody mediated immu-
nity in the control of the disease in chickens [107]. 
Studies have shown evidences demonstrating the pres-
ence of CD8+ T cells against MDV antigens such as: gB, 
Meq, pp38 and ICP4. However, the role of CTL in con-
ferring long term immunity, generation of memory cells, 
in genetically resistant chickens is unknown [36] and the 
role of cell-mediated immunity in vaccine-induced pro-
tection has not been determined. No cytotoxic response 
against ICP22 and a weak cytotoxicity against Meq 
were detected in MDV-infected chickens [5, 26]. Other 
studies confirmed the presence of anti-gB and anti-gI 
TCRαβ1+ CD8+ T cells with cytotoxic abilities in MDV-
infected birds [108].
The presence of herpes virus specific CD8+  T cell 
response coincides with protection from cytomegalovirus 
(CMV) infection and adoptive cell transfer of CD8+  T 
cells provide protection in animal models. The impor-
tance of CD4+  T cells in providing protection against 
herpes virus infection was also demonstrated by CD4+ T 
cell depletion experiments in animal models. There was 
an inverse correlation between the number of virus-spe-
cific CD4+  T cells and prolonged shedding [105, 106]. 
Therefore, it is very likely that both CD8+ and CD4+ T 
cells are involved in the control of MDV replication. This 
notion is confirmed with the early studies showing that 
T cells are crucial for the control of tumour growth in 
HVT-vaccinated chickens. The importance of T cells in 
the control of tumour growth was confirmed by demon-
strating that HVT vaccinated birds treated with cyclo-
sporine, a drug shown to inhibit T cell function, develop 
MDV-lymphoma [109, 110]. However, later studies sug-
gested that T cells are only involved in the control of viral 
replication but not essential for the control of tumour 
growth [111]. Further studies are required to confirm 
the exact role of CD4+ and CD8+ T cells in the control 
of MDV replication and tumour growth. The availabil-
ity of CD4+  and CD8+  knockout chicken will provide 
valuable tools to study the role of these cells in vaccine-
induced protective immunity against viral replication and 
tumour growth. MHC-determined resistance to MDV 
in MHC:B21/B21 birds indirectly confirms the role of T 
cells in control of tumour development. For MHC class I 
molecules, the relative level of expression varies between 
different MHC haplotypes and reflects the consensus 
hierarchy of response by different MHC haplotypes with 
the most susceptible chickens (MHC B19/B19) having 
the highest expression while the most resistant chick-
ens (MHC: B21/B21) expressing the lowest level [112]. 
It is believed that the differences in cell surface expres-
sion level ensure the development of optimal peripheral 
T cell responses against MDV. The detection of MDV-
specific CD8+  T cells with cytotoxic ability to recog-
nize target cells expressing MDV antigen is technically 
challenging. However, Schat and Markowski-Grimsrud 
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developed a heterologous system to investigate cyto-
toxic T cell response to MDV using reticuloendothelial 
virus-transformed cells stably transfected with specific 
MDV genes [99]. The cell lines derived from resistant 
(MHC: B21/B21) and susceptible (MHC: B19/B19) birds 
were generated and antigen-specific cytotoxicity were 
analysed in  vitro. The cytotoxicity was low compared 
to mammalian cytotoxic T lymphocyte (CTL) assays 
[5]. In these studies, relatively a more potent cytotoxic-
ity was detected against target cells expressing pp38 and 
gB antigens. No cytotoxic response against ICP22 and a 
weak cytotoxicity against Meq were detected in MDV-
infected chickens [5, 26]. Other studies confirmed the 
presence of anti-gB and gI TCRαβ1+ CD8+ T cells with 
cytotoxic abilities in MDV-infected birds [108]. Vacci-
nation of chickens with a recombinant Fowl Pox Virus 
(FPV) expressing these two glycoproteins have been 
reported to induce protective immunity when challenged 
with MDV and shown to induce anti-MDV neutraliz-
ing antibodies [113, 114]. Recombinant FPV expressing 
gB was later shown to induce cytotoxic T cell response 
recognizing target cells expressing gB [115]. These data 
support the importance of anti-MDV CD8+  T cells 
responses in the control of the disease, however, the role 
of MDV-specific CD8+  T cell responses in the control 
of viral infection or tumour growth in birds immunized 
with HVT or CVI988-Rispens is still unknown. In addi-
tion, there is very little information on the magnitude 
and quality of MDV-specific T cells responses in resist-
ant vs. susceptible chickens. The only available informa-
tion suggest that anti-ICP4 CD8+  T cell responses is 
only detected in the resistant chickens [26], while anti-gE 
CD8+ T cell response is only detected in the susceptible 
chickens. These results suggest that the response to ICP4, 
an immediate early MDV gene product, but not to gE 
may be an important factor in genetic resistant to MDV. 
It has been shown that CTL responses characterized by 
release perforin and granzymes can be induced against 
MDV antigens such as PP38, Meq and ICP4 [36]. Moreo-
ver, there is still no information on the presence of MDV-
specific CD4+ T cell responses and whether transformed 
CD4+  T cells have antigen specificity to MDV anti-
gens. Further studies are required to identify CD4+ and 
CD8+  T cell epitopes within MDV antigens and deter-
mine their MHC restriction. Moreover, it is important to 
examine the quality, broadness, durability and magnitude 
of the CD4+  and CD8+  T responses in MDV infected 
or vaccinated chickens and determined the correlates 
between T cell responses and protection.
In addition to T cell responses against MDV viral anti-
gens, it is possible that T cells may also recognize self-
antigens expressed by tumour cells. However, the nature 
of these self-antigens and their relevance to immunity and 
inhibition of tumour growth in birds is still unknown. A 
few decades ago, Marek’s disease tumour-associated sur-
face antigens (MATSA) was identified in the MDV-trans-
formed T cells [116]. However, it was later discovered 
that activated T cells can also express MATSA antigens, 
and this molecule is not solely expressed on transformed 
T cells [117]. Several of these MATSA are found to be 
activation associated lymphocyte antigens, and one of 
them is identified as CD30 molecule [47]. Meanwhile 
CD30, a co-stimulatory molecule, has been shown to 
have pleiotropic effects on human T cell activation, apop-
tosis, effector function (cytotoxicity) and regulating T 
cell trafficking/migration [118]. It has a fundamental role 
across all T cell lineages such as CD4+ , CD8+ and Th17 
cells [119] and may influence T cell interaction; suppres-
sive action in the tissue microenvironment.
Immunomodulatory processes that influence CTL 
functional abilities in relation to persistent viral infec-
tion and tumorigenesis may be mediated via interaction 
of inhibitory receptors such as CTLA4, programmed 
death-1 (PD-1) and its respective ligand programmed 
death ligand-1 (PD-L1). The evidence suggests that 
MDV infection up-regulate the expression of CTLA-4, 
PD1 and PD-L1 in chicken immune system cells. The 
expression level of PD-1 was increased in chickens at 
the early cytolytic phase of the MDV infection, while 
the PD-L1 expression level was increased at the latent 
phase. In addition, the expression levels of PD-1 and 
PD-L1 were increased at tumor lesions found in MDV-
infected chickens [120, 121]. Furthermore, T cell respon-
siveness may be affected by chronic antigen stimulation 
leading to exhaustion thus altering phenotypic char-
acteristics such as PD-1 expression also observed dur-
ing in  vitro MDV infection. A combination of reduced 
MHC-I and increased PD-1 cell surface transloca-
tion provides a platform for highly efficacious immune 
evasion tactic. CTLA-4, a potent inhibitory receptor, 
expressed by CD4+ T cells has also be reported during 
the early cytolytic phase in MDV infected birds [120]. 
Significant differences in CTLA-4 and PD-1 expres-
sion levels, which could result in a delayed immune 
responsiveness (anergy) and cell death respectively, 
were reported between resistant and susceptible lines 
of chickens challenged with MDV. A similar pheno-
type has been reported in patients infected with human 
alpha-herpes viruses such as VZV whereby CD4+ T cell 
predominantly express CTLA-4 and PD-1 [122]. Induc-
tion of an early immune unresponsiveness (anergy) and 
cytolysis (4–7 dpi) could well be a hallmark, for alpha-
herpes viruses, to establish early semi-productive viral 
replication and disseminated viraemia. Blocking or 
down regulating CTLA-4 or PD-L1 could be therapeu-
tically significant during early infection. Furthermore, 
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PD-L1 expression results in immune suppression thus 
can be used as a marker for CD4+  T cell lymphoma. 
PD-L1 expression in MDV challenged chickens, could 
limit the quality of T cells immune responsiveness to 
Meq, pp38, ICP4 or gB at the immunological synapse 
(Figure  5). PD-1 and CTLA-4 ligation with its cognate 
receptor results in cross-pathway interference result-
ing in inhibition of RAS, ERK 1/2, AKT, JNK and PLCγ 
phosphorylation altering cell fate; growth/proliferation, 
effector function and survival. Expression of inhibitory 
molecules on both antigen presenting cells can lead to 
the generation of chicken regulatory CD4+ T cells (Treg 
cells). The role of naturally occurring and peripheral 
derived Treg cells in modulation of anti-MDV immunity 
is still unknown. However, it is known that MDV infec-
tion up-regulates the expression of inhibitory molecules 
such as CTLA-4 and expression of inhibitory cytokines 
such as IL-10. The expression of regulatory molecules 
such as CTLA-4 and IL-10 on both CD4+ and CD8+ T 
cells are at 10 and 21 dpi and this effect was more pro-
nounced in the MDV-susceptible chicken lines [123].
4  Persistence in the face of vaccination
Vaccination against MD started in the late 1960s using 
turkey herpesvirus (HVT) which does not induce dis-
ease in chickens. The vaccination reduced the inci-
dence of MD by 99% and was the first successful vaccine 
against naturally occurring virus-induced cancer. Since 
then MDV has evolved, perhaps due to vaccine induced 
immune response, and the escape of new mutants from 
immune pressure. Currently only attenuated MDV 
strain; CVI988-Rispens is effective in providing protec-
tion against the very virulent MDV. Live vaccines are 
administered either to day-old chicks or to the 18-day-
old embryo. MDV vaccine inhibits the development of 
MDV-induced lymphoma but does not prevent infection 
and replication of pathogenic strains of MDV. Both vac-
cination and maternal antibodies against MDV increases 
viral shedding and onward transmission of hyper-vir-
ulent strains of MDV due to the survival of the host 
without controlling the virus shedding [124]. The failure 
of current vaccines to induce sterile immunity can be 
attributed to MDV inducing latency with minimal viral 
Figure 5 T cell activation and tolerance by tumour cells/antigen presenting cells. Inhibitory or stimulatory molecules expressed on the 
surface of antigen presenting cells (APC) or tumour cells regulate T cell function. Moreover, stimulatory or inhibitory cytokines may drive the 
generation of different T cell populations (e.g. Th1, Th17, Treg etc.) with diverse functional properties. Signal one is provided to the T cell receptor of 
T cells by presentation of antigens via MHC class I or II molecules expressed by APCs or tumour cells, while the signal 2 is provided by co-stimulatory 
molecules such as B7 family. Co-stimulatory signals induce the generation of effector T cells, which can recognize and lyse target cells or produce 
cytokines such as IFN-γ, involved in the control of tumour growth. In contrast, inhibitory molecules deliver negative signals and suppressing the 
effector T cell function, and induce T cell anergy or exhaustion.
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replication and viral protein expression. The ideal MDV 
vaccine is to control both the disease and viral shed-
ding in the infected birds. Revaccination (prime-boost) 
with the current cell-associated MDV vaccine (CVI988-
Rispens) improve protection against the disease and 
increases the magnitude of anti-MDV T cell responses 
as demonstrated by enhancement of anti-MDV neutral-
izing antibody and proliferation of CD4+ and CD8+ T 
cells [125]. However, the type and quality of immunity 
after even revaccination with the current MDV vac-
cines cannot control virus shedding. Further research 
is required to understand immune responses required 
to control MDV shedding as well as the control of the 
disease. To generate more effective vaccines against 
MDV, we need to (a) have a better understanding of 
the type of immunity required for reducing viral shed-
ding/inducing sterile immunity (b) design a vaccine that 
can induce protective immunity against the virus. It is 
believed that the quality, broadness, durability and hom-
ing of both CD4 and CD8 T cell responses may explain 
why vaccines against some alpha-herpes viruses (VZV) 
are more effective than vaccines against other alpha-
herpes viruses (HSV) [126]. As yet there is little infor-
mation as to whether cell-mediated immunity is induced 
by the MDV vaccine. The lack of established methodol-
ogy to assess cell-mediated immunity to MDV vaccine 
is the major obstacle to have a better understanding of 
how MDV vaccine actually works. It is very likely that 
the induction of both innate and adaptive immune 
responses by vaccine strain is similar to those induced 
by pathogenic MDV [93, 127]. Cytokine response fol-
lowing oncogenic and vaccine strains of MDV has also 
been reported and the results demonstrate that very 
virulent virus (vvMDV), compared with vaccine strain 
(CVI988/Rispens), induced similar levels of the typi-
cal Th1-type cytokine IFN-γ in microglia in vitro, while 
vvMDV induces higher expression of IL-12 (p40), IL-8, 
and MIP-1β [128].
It is postulated that vaccine-induced adaptive immu-
nity plays a major role in providing protection against 
the disease. There are some evidences demonstrating that 
a number of MDV antigens, including gB when admin-
istered as recombinant vaccine in a fowl pox vector, are 
immunogenic and immunity to these antigens confers 
protection [115]. However, the types and magnitude 
of vaccine-induced protective immune responses to 
these antigens are still unknown. Several factors includ-
ing genetic background of chickens [129], presence or 
absence of maternal antibodies, virulence of MDV, vac-
cine dose [130] and concurrent infections with other 
immunosuppressive pathogens such as CIAV [108] can 
influence the efficacy of MDV vaccines.
A medley of growth factors and cytokines such as 
myelomonocytic growth factor (MGF) [131] and IFN-γ 
[83] have been considered as immuno-modulators and 
vaccine adjuvants against MDV. The treatment of MDV-
susceptible chickens with MGF, a growth and activation 
factor for monocytes/macrophages, reduced viral load, 
increased survival rate and reduced tumour incidence 
after challenge [131]. It is postulated that MGF increases 
the number of macrophages and their response to stimuli 
as shown by an increase in NO production by activated 
macrophages. Similarly, we have recently shown that 
administering HVT vaccine with a plasmid express-
ing recombinant chicken IFN-γ enhanced the protective 
efficacy of the vaccine against MDV and reduced viral 
load and tumour incidence [83]. IL-18 has been shown 
to stimulate IFN-γ production from CD4+  T cells and 
can also indirectly stimulate CD8+  T cell proliferation 
[132]. In addition, IFN-γ can enhance the development 
of Th1 type responses which is known to be important 
in the control of viral infections as well as activating 
innate immune cells such as macrophages and NK cells. 
Although not explored in chickens, classical activation of 
IFN-γ results in interferon stimulatory gene (ISG)-1 up 
regulation, which could have an additive antiviral effect. 
Both type I and type II interferons have been tested in 
various clinical settings but the whole gamete of IFN-
regulated signalling pathways have yet to be elucidated. 
Ligands for TLRs are used as adjuvants that stimulate 
immune responses, leading to protection against infec-
tious diseases. We have demonstrated that the admin-
istration of TLR3 [133], TLR4 and TLR21 ligands [134] 
reduces the incidence of tumours and MDV genome copy 
numbers in the infected birds. The importance of TLR 
in providing protection against tumour development 
could be extrapolated from the results demonstrating 
significantly higher basal expression levels of TLR3 and 
TLR7 in uninfected chicken cells isolated from resistant 
chicken lines compared to the susceptible lines [135].
5  Conclusions
Our understanding of innate and adaptive immunity to 
MDV infection is continuously improving. This grow-
ing knowledge can be further enhanced by our under-
standing of immunity to human alphaherpesviruses and 
host-pathogen interaction. However, there are many 
differences between the human and avian immune sys-
tem as well as different characteristics between MDV 
and human alphaherpesviruses (VZV, HSV1 and 2). For 
example, MDV is the only alphaherpesviruses that can 
modulate the chemokine network by molecular mim-
icry of a host protein and thus recruit, infect and trans-
form CD4+ T cells. In terms of vaccine development, the 
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developments of potent cell-free vaccines that can inhibit 
infection as well as the disease are paramount to research 
in this area.
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